Question 1

What is BAM15?

Accepted Answer

BAM15 is a lab-made chemical that changes how mitochondria behave, mitochondria being the compartments inside a cell that convert food into usable energy. It was named in 2014, as a new uncoupler that does not depolarize the plasma membrane. That last part is what separated it from the older chemicals of its type, because it acts on the inner wall of the mitochondria and leaves the outer wall of the cell alone. A 2025 chemistry paper describes the whole class in one line: these are fatty small molecules that carry protons into the mitochondria, uncoupling nutrient oxidation from ATP production. ATP is the fuel a cell spends to do anything at all. Loosen the link between burning food and making ATP, and more food has to be burned for the same result. A 2023 review puts the upshot plainly: BAM15 dissipates the proton gradient, which raises mitochondrial respiration and energy expenditure. That one idea, wasting a little energy on purpose, runs underneath every finding on this page.

Question 2

Is BAM15 a peptide?

Accepted Answer

No, and the gap between how it is searched and what it is matters, because the word peptide carries an expectation about how a compound behaves in the body. A 2026 mouse liver study gives its full chemical name as N5,N6-bis(2-Fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine, a ring structure carrying two fluorinated benzene groups and no amino acids at all. A 2020 obesity paper describes it the same way, as a mitochondrially targeted small molecule protonophore. The practical difference is that peptides are chains of amino acids, which stomach enzymes break apart, and that is why so many of them are injected. BAM15 is not built that way, and the 2020 work reports instead that it is orally bioavailable in mice, meaning enough of it survives the gut to reach the bloodstream when eaten. A reader who arrived expecting peptide behaviour is therefore reading about a different kind of molecule with a different set of questions attached to it.

Question 3

Does BAM15 really work?

Accepted Answer

In mice, the metabolic effect has been reproduced by several laboratories, which is more than most compounds covered on this site can claim. The 2020 obesity paper reports that BAM15 increased nutrient oxidation and decreased body fat mass in mice without altering food intake, lean body mass, body temperature, or the blood markers of toxicity that were measured. A separate 2020 group found that mice given BAM15 were resistant to weight gain on a fattening diet. A 2023 experiment in diabetic db/db mice, which carry a genetic fault that makes them obese and severely hyperglycaemic, found that the higher amount normalized fasting glucose and glucose tolerance to levels similar to lean control mice. Read what that sentence is and is not. It is a repeated result in rodents bred to be metabolically ill, measured over weeks, and it says nothing yet about a person, because the step into people has not been taken in the research covered here.

Question 4

Has BAM15 been given to people?

Accepted Answer

Not in any study among the research behind this page, and the three closest approaches are worth describing exactly, because each one stops short in a different way. The nearest thing to a living body is a 2020 imaging experiment in which preliminary dose response experiments were conducted in two pigs to find the concentration of BAM15 infusate needed to shift a radioactive tracer. That was an infusion into the heart arteries of anaesthetised animals, done to test an imaging method rather than to look for any benefit. Human cells have been exposed to it outside the body. A 2023 reproductive study found that BAM15 specifically uncoupled human sperm mitochondria while a second uncoupler also depolarized the surrounding cell membrane. A 2026 follow-up reports that in frozen and thawed human sperm, BAM15 increased total and progressive motility and improved viability compared with untreated controls. Cells in a dish are not a person: nothing there passes through a liver, a kidney or a bloodstream, which is where the questions about an uncoupler actually live.

Question 5

What has BAM15 been used for in the research?

Accepted Answer

The published work is considerably wider than the weight-loss framing suggests, and most of it is mouse work aimed at a particular disease rather than at body composition. A 2023 kidney paper gave BAM15 to mice with blood poisoning, and reports that it reduced mortality, even after 12 hours, when the mice were ill. Those mice were also given fluids and antibiotics, which is the supportive care a person with that illness would receive. A 2025 study reports that oral BAM15 suppressed artery disease in western-diet-fed mice lacking a gene for clearing fat, and improved their blood fats. In cancer models, a 2021 breast cancer paper reports that in lean mice, BAM15 lowered body weight independent of food intake and slowed tumor progression. What each of those outcomes was measured as, and in which animals, is laid out on the BAM15 benefits page rather than repeated here.

Question 6

What do the reviews of BAM15 say?

Accepted Answer

Several reviews cover BAM15 directly. They agree on the shape of the evidence, and they end on the same unfinished business. The 2023 review names obesity, diabetes, fatty liver disease, sepsis and heart disease as the settings where BAM15 has done something, then closes on its high lipophilicity and the need for alternative delivery methods. Lipophilic means it dissolves in fat, not water. That is a formulation problem before it is anything else. A 2025 review of blood-vessel damage in diabetes is more guarded, closing on the point that further research is needed to evaluate its long-term vascular effects in diabetic models. Note what kind of reviews those are: summaries of animal data, written by scientists for other scientists. No source covered here reports what a person experienced after taking BAM15, and an absence of reports does not tell you anything about how it behaves in a body.

Question 7

Can mitochondrial uncouplers help with weight loss?

Accepted Answer

The class has a long history in obesity, and it is not an encouraging one, which is the context any BAM15 result sits inside. A 2001 review states the rationale directly: mitochondrial proton cycling accounts for a significant share of resting metabolic rate, so uncoupling further is a plausible way to raise energy expenditure. The same review notes that uncoupling by 2,4-dinitrophenol has been used in this way in the past with notable success. A 2022 review supplies the other half of that sentence, describing medications that replicate brown fat metabolism by uncoupling as effective for weight loss but limited by toxicity to a narrow therapeutic range. Narrow therapeutic range means the gap between an amount that does something and an amount that harms is small. What that history consists of is set out on the BAM15 safety page, and the amounts behind the animal results are on the BAM15 dosage page.

Question 8

How is BAM15 different from 2,4-dinitrophenol?

Accepted Answer

The field keeps making this comparison. The published difference is about where each molecule acts, not about how strongly it acts. The older chemicals, 2,4-dinitrophenol among them, have off-target activity at other membranes that lead to a range of undesired effects. The 2014 paper that named BAM15 lists cell death among them, and that is what narrows the gap between a useful amount and a damaging one. Against that benchmark, the same paper reports that BAM15 treatment of cultured cells stimulates a higher maximum rate of mitochondrial respiration and is less cytotoxic, meaning less toxic to the cell. A 2026 mouse study adds that BAM15 has a higher binding capacity and stronger activity in mediating proton uncoupling than the two older chemicals. Being cleaner in a dish is a real finding, and a narrow one. The problems that ended the 2,4-dinitrophenol story showed up in people, not in cells.

Question 9

What is the half-life of BAM15?

Accepted Answer

No source among the research behind this page gives a half-life for BAM15 itself, in any species. That is an awkward gap for a molecule people are asking how often to take. What the literature holds instead are figures belonging to molecules built from it, and to formulations built around it. A 2022 paper wrapped BAM15 in albumin particles, which it reports improve aqueous solubility and half-life of BAM15. That tells you the plain molecule has a problem on both counts, without putting a number on either one. A 2026 chemistry paper reports a half-life of 13 h in mice, but for a derivative, not for BAM15. A 2025 paper on a different set of derivatives found a short half-life of 15 to 27 minutes in mice. A half-life measured for a derivative cannot be read as the parent's, and the reason chemists keep building derivatives is that the parent is awkward to work with.

Question 10

How was BAM15 given in the studies?

Accepted Answer

Three routes appear in the animal work, and the one chosen usually follows from what the experiment was asking. Most of the metabolic studies mixed it into food: the 2022 muscle-ageing experiment randomized 80-week-old obese male mice to 10 weeks of high fat diet alone or the same diet carrying BAM15. Injection appears in the disease models, for instance the 2025 artery study in which BAM15 was given under the skin daily. A 2026 engineering paper went a third way, loading BAM15 into a microneedle patch alongside capsaicin so that each one releases into fat tissue at a different speed. The amounts attached to each of those routes, and why none of them converts into a figure for a person, are reported on the BAM15 dosage page.

Question 11

What is documented about harm from BAM15?

Accepted Answer

The honest summary is that the harm record is an animal record, collected over weeks, by people measuring something else. The 2025 side-by-side comparison of 15 uncouplers analysed plasma for markers of toxicity at the end of four weeks of treatment in diabetic mice, and BAM15 came through that screen with the best overall effects on body weight, glucose control and liver fat of the molecules tested. Away from mammals, a 2026 study found that BAM 15 possesses strong molluscicidal activity against an invasive freshwater snail, killing juveniles at the lowest concentrations tested. A molecule that kills a snail by collapsing its mitochondria is doing the same thing it does in a mouse, at a different scale, which is the reason dose matters so much in this class. A 2021 review of uncouplers in cancer puts the open question in one line: the long-term safety of some uncouplers remains in question. What is documented adverse effect by adverse effect, and what the class history adds, is taken apart on the BAM15 safety page.

Question 12

Is BAM15 legal, and is it approved?

Accepted Answer

No approval for any use in people is documented in the research behind this page, and the reviews describe BAM15 as a candidate rather than a medicine. A 2020 obesity paper calls its own work the first demonstration of pre-clinical efficacy for BAM15, which is the language of a compound at the start of development. The history of the class is worth knowing here, because it is the nearest thing to a precedent. A 2019 review records that 2,4-dinitrophenol was used in the 1930s at high doses for obesity in well over 100,000 humans, and that it has never been an FDA-approved drug. A 2020 review of European food alerts found the major adulterant in illegal weight-loss supplements, 113 of 319 products, was DNP. Both of those are facts about a different molecule in the same class. They are the backdrop any uncoupler sold outside a pharmacy gets read against.

Question 13

What is actually in material sold as BAM15?

Accepted Answer

No analysis among the research behind this page has measured the identity, strength or purity of anything sold under this name. For a reader, that is the largest unknown on the page. Every result here comes from material made to a laboratory recipe and handled by the chemists who synthesised it. That recipe is exact. The 2015 structure paper shows the importance of the furazan, pyrazine, and aniline rings as well as pKa in maintaining its effective protonophore activity. Those are the three rings the molecule is built from, and pKa is a measure of how readily the structure gives up a proton. Read what that means for a vial. Small changes to the structure change how hard it uncouples, and in this class the gap between a useful amount and a harmful one is already narrow. The 2025 comparison of 15 uncouplers makes the broader point, concluding that mitochondrial uncouplers should not be generalized. Buying under a class name rather than a verified structure is the exact situation that sentence warns against.

Question 14

How does BAM15 work?

Accepted Answer

Mitochondria normally pump protons out and let them back in through a turbine-like enzyme, capturing the energy as ATP. An uncoupler opens a second door, so some of that energy leaves as heat instead. A 2021 membrane study confirmed BAM15 behaves as a classic anionic protonophore, and found that in isolated rat liver mitochondria it collapsed the membrane potential, increased the respiration rate and caused calcium to leave the organelle. Downstream of that, cells read the drop in available energy as a signal to start burning reserves. A 2018 blood-vessel study found that BAM15 potently activated AMPK, the enzyme a cell uses to sense that its energy is running low, more strongly in those cells than metformin did. A 2026 mouse study ties the same signal to the liver result, reporting that BAM15 improved hepatic lipid metabolism disorders by enhancing mitochondrial autophagy through that pathway, meaning the cell recycles its own damaged mitochondria. The same low-energy signal is what MOTS-c is studied for on the MOTS-c overview, from the opposite direction, and SS-31 on the SS-31 overview works on mitochondria without uncoupling them at all.

BAM15